ARTIVION, INC. Revenue
ARTIVION, INC. (AORT) reported Revenue of $125.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $125.76M, a 11.32% increase year-over-year.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $116.34M, a 17.54% increase year-over-year.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $115.99M, a 19.20% increase year-over-year.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $113.39M, a 18.39% increase year-over-year.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $441.33M, a 13.59% increase from fiscal 2024.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $388.54M, a 9.75% increase from fiscal 2023.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $354.00M, a 12.82% increase from fiscal 2022.
- ARTIVION, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $313.79M, a 5.00% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $125.76M 10-Q · filed 2026-08-07 | $242.09M 10-Q · filed 2026-08-07 | $358.09M derived: sum of 3 quarters · filed 2026-08-07 | $471.47M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $116.34M 10-Q · filed 2026-05-08 | $232.33M derived: sum of 2 quarters · filed 2026-05-08 | $345.72M derived: sum of 3 quarters · filed 2026-05-08 | $458.69M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $115.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $229.38M derived: sum of 2 quarters · filed 2026-02-18 | $342.35M derived: sum of 3 quarters · filed 2026-08-07 | $441.33M 10-K · filed 2026-02-18 | |
| 2025-09-30 | $113.39M 10-Q · filed 2025-11-07 | $226.36M derived: sum of 2 quarters · filed 2026-08-07 | $325.34M 10-Q · filed 2025-11-07 | $422.65M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $112.97M 10-Q · filed 2026-08-07 | $211.95M 10-Q · filed 2026-08-07 | $309.26M derived: sum of 3 quarters · filed 2026-08-07 | $405.04M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $98.98M 10-Q · filed 2026-05-08 | $196.29M derived: sum of 2 quarters · filed 2026-05-08 | $292.06M derived: sum of 3 quarters · filed 2026-05-08 | $390.08M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $97.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $193.09M derived: sum of 2 quarters · filed 2026-02-18 | $291.11M derived: sum of 3 quarters · filed 2026-02-18 | $388.54M 10-K · filed 2026-02-18 | |
| 2024-09-30 | $95.78M 10-Q · filed 2025-11-07 | $193.80M derived: sum of 2 quarters · filed 2025-11-07 | $291.23M 10-Q · filed 2025-11-07 | $384.90M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-06-30 | $98.02M 10-Q · filed 2025-08-08 | $195.45M 10-Q · filed 2025-08-08 | $289.12M derived: sum of 3 quarters · filed 2026-02-18 | $376.97M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-03-31 | $97.43M 10-Q · filed 2025-05-06 | $191.10M derived: sum of 2 quarters · filed 2026-02-18 | $278.95M derived: sum of 3 quarters · filed 2026-02-18 | $368.21M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2023-12-31 | $93.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $181.52M derived: sum of 2 quarters · filed 2026-02-18 | $270.77M derived: sum of 3 quarters · filed 2026-02-18 | $354.00M 10-K · filed 2026-02-18 | |
| 2023-09-30 | $87.85M 10-Q · filed 2024-11-08 | $177.10M derived: sum of 2 quarters · filed 2024-11-08 | $260.33M 10-Q · filed 2024-11-08 | $339.73M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $89.25M 10-Q · filed 2024-08-09 | $172.48M 10-Q · filed 2024-08-09 | $251.88M derived: sum of 3 quarters · filed 2025-02-28 | $328.72M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $83.23M 10-Q · filed 2024-05-07 | $162.63M derived: sum of 2 quarters · filed 2025-02-28 | $239.47M derived: sum of 3 quarters · filed 2025-02-28 | $319.81M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $79.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $156.24M derived: sum of 2 quarters · filed 2025-02-28 | $236.58M derived: sum of 3 quarters · filed 2025-02-28 | $313.79M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $76.84M 10-Q · filed 2023-11-03 | $157.18M derived: sum of 2 quarters · filed 2023-11-03 | $234.39M 10-Q · filed 2023-11-03 | $313.79M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | $80.34M 10-Q · filed 2023-08-04 | $157.55M 10-Q · filed 2023-08-04 | $236.95M derived: sum of 3 quarters · filed 2024-02-23 | $309.15M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $77.21M 10-Q · filed 2023-05-05 | $156.61M derived: sum of 2 quarters · filed 2024-02-23 | $228.81M derived: sum of 3 quarters · filed 2024-02-23 | $304.96M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $79.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $151.60M derived: sum of 2 quarters · filed 2024-02-23 | $227.75M derived: sum of 3 quarters · filed 2024-02-23 | $298.84M 10-K · filed 2024-02-23 | |
| 2021-09-30 | $72.21M 10-Q · filed 2022-11-04 | $148.35M derived: sum of 2 quarters · filed 2022-11-04 | $219.44M 10-Q · filed 2022-11-04 | $287.34M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $76.15M 10-Q · filed 2022-08-05 | $147.24M 10-Q · filed 2022-08-05 | $76.15M 10-Q · filed 2021-07-30 | $215.13M derived: sum of 3 quarters · filed 2023-02-23 | $280.26M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $71.09M 10-Q · filed 2022-05-06 | $138.98M derived: sum of 2 quarters · filed 2023-02-23 | $204.11M derived: sum of 3 quarters · filed 2023-02-23 | $257.88M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $67.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $133.03M derived: sum of 2 quarters · filed 2023-02-23 | $186.80M derived: sum of 3 quarters · filed 2023-02-23 | $253.23M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $65.13M 10-Q · filed 2021-11-05 | $118.90M derived: sum of 2 quarters · filed 2021-11-05 | $185.33M 10-Q · filed 2021-11-05 | $255.03M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-06-30 | $53.77M 10-Q · filed 2020-07-31 | $53.77M 10-Q · filed 2021-07-30 | $120.20M 10-Q · filed 2020-07-31 | $189.90M derived: sum of 3 quarters · filed 2022-02-22 | $257.78M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $66.43M 10-Q · filed 2021-04-30 | $136.13M derived: sum of 2 quarters · filed 2022-02-22 | $204.01M derived: sum of 3 quarters · filed 2022-02-22 | $275.15M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2019-12-31 | $69.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $137.58M derived: sum of 2 quarters · filed 2022-02-22 | $208.72M derived: sum of 3 quarters · filed 2022-02-22 | $276.22M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $67.88M 10-Q · filed 2020-11-05 | $139.02M derived: sum of 2 quarters · filed 2020-11-05 | $206.53M 10-Q · filed 2020-11-05 | $274.32M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-06-30 | $71.14M 10-Q · filed 2020-07-31 | $138.64M 10-Q · filed 2020-07-31 | $206.44M derived: sum of 3 quarters · filed 2021-02-23 | $271.04M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-03-31 | $67.50M 10-Q · filed 2020-05-01 | $135.30M derived: sum of 2 quarters · filed 2021-02-23 | $199.90M derived: sum of 3 quarters · filed 2021-02-23 | $268.40M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2018-12-31 | $67.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $132.40M derived: sum of 2 quarters · filed 2021-02-23 | $200.89M derived: sum of 3 quarters · filed 2021-02-23 | $262.84M 10-K · filed 2021-02-23 | |
| 2018-09-30 | $64.60M 10-Q · filed 2019-10-31 | $133.09M derived: sum of 2 quarters · filed 2019-10-31 | $195.04M 10-Q · filed 2019-10-31 | $247.87M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-06-30 | $68.50M 10-Q · filed 2019-07-31 | $130.44M 10-Q · filed 2019-07-31 | $183.27M derived: sum of 3 quarters · filed 2020-02-19 | $227.27M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-03-31 | $61.95M 10-Q · filed 2019-05-02 | $114.77M derived: sum of 2 quarters · filed 2020-02-19 | $158.77M derived: sum of 3 quarters · filed 2020-02-19 | $206.59M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2017-12-31 | $52.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $96.83M derived: sum of 2 quarters · filed 2020-02-19 | $144.64M derived: sum of 3 quarters · filed 2020-02-19 | $189.70M 10-K · filed 2020-02-19 | |
| 2017-09-30 | $44.00M 10-Q · filed 2018-11-01 | $91.82M derived: sum of 2 quarters · filed 2018-11-01 | $136.88M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $47.82M 10-Q · filed 2018-08-07 | $92.88M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $45.06M 10-Q · filed 2018-05-04 | ||||
| 2016-12-31 | $180.38M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |